Development of novel glyco-biomarkers for nonalcoholic steatohepatitis (NASH) based on the adipocytokine dysregulation

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590972
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Osaka University
• Principal Investigator: KAMADA YOSHIHIRO 大阪大学, 医学(系)研究科(研究院), 准教授 (30622609)
• Co-Investigator(Kenkyū-buntansha): MIYOSHI Eiji 大阪大学, 医学系研究科, 教授 (20322183)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 肝臓病 / 糖鎖 / バイオマーカー

Outline of Final Research Achievements

Nonalcoholic steatohepatitis (NASH) is a growing medical problem, and can progress to liver cirrhosis and hepatocellular carcinoma. Now, liver biopsy remains the gold standard for the diagnosis and the grading liver disease severity in NASH patients. However, liver biopsy is an invasive test, and repeated liver biopsy for the estimation of NASH progression is hard to perform. Therefore, noninvasive NASH biomarkers are needed. We investigated pathophysiology of NASH focusing on adipocytokine and oligosaccharide. We found that lack of secreted frizzled related protein 5 accelerated the liver fibrosis progression. In addition, we established three glyco-biomarkers for NASH. Serum fucosylated haptoglobin and Mac-2 binding protein levels are useful for the NASH diagnosis, and suitable for the prediction of ballooning hepatocyte presence and liver fibrosis severity, respectively. We also found serum fetuin-A levels were decreased with the liver fibrosis progression of NASH patients.

Free Research Field

肝臓病学